CERO Therapeutics Holdings, Inc. announced on February 5, 2025, the pricing of a public offering expected to generate approximately $5 million in gross proceeds. The offering includes the sale of 2,551,020 shares of its common stock, or common stock equivalents, and warrants to purchase an equal number of shares.
The combined purchase price for each share and accompanying warrant is $1.96. The warrants will have an exercise price of $1.96 per share, will be immediately exercisable upon stockholder approval, and will expire five years from the initial exercise date.
The company intends to allocate the net proceeds from this offering towards the advancement of its clinical programs and for general working capital purposes. The closing of the offering is anticipated to occur on or about February 7, 2025, subject to customary closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.